SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock following its earnings report, which, despite beating estimates, has been overshadowed by concerns regarding the Warner Bros Discovery acquisition. The community is sharply divided, with bulls viewing the current dip as an oversold opportunity for long-term content expansion, while bears cite the deal's cost, debt implications, and paused share buybacks as reasons for further downside. This strategic move and its perceived impact on future margins are driving intense discussion and significant price action.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network ($BNAI) is experiencing significant market attention following news of a strategic AI licensing partnership in Africa, including a pilot program with Nelson Mandela University. This development, combined with discussions around a reportedly thin float and high short interest, is driving substantial pre-market volatility and community speculation about a potential short squeeze. Traders are actively monitoring for sustained momentum, positioning BNAI as a key focus within the AI sector narrative.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending with immense community excitement, primarily driven by the high anticipation of potential PMDA Japan approval for its Alpha DaRT therapy, following compelling pancreatic cancer data. Investors are increasingly bullish, viewing recent strong clinical updates and growing institutional interest as key catalysts for this innovative oncology technology, which many believe is poised for significant recognition.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to immediate market uncertainty surrounding an anticipated speech by Donald Trump at Davos, sparking community debate over potential tariffs and geopolitical tensions, particularly regarding Greenland. Sentiment is split, with some traders concerned about rising Japanese bond yields and broader market weakness, while others expect a rebound, highlighting underlying economic resilience and a potential rotation into small-cap and value stocks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is experiencing a parabolic rally to new record highs, driven by escalating global trade tensions and broad geopolitical uncertainty. The community is actively discussing gold's role as a safe haven amidst concerns over sovereign debt, potential currency debasement, and central bank diversification, fueling significant short-covering and strong bullish momentum.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility and declines as natural gas futures surge dramatically, driven by widespread "Arctic Blast" weather forecasts across the US. This rapid price action is causing extreme pressure for many traders, leading to discussions of a "widowmaker" market as some cautiously "buy the dip" on KOLD while others are caught in the squeeze.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as President Trump's aggressive rhetoric regarding Greenland and potential new tariffs, coupled with concerns over Japan's bond market, fuels a broad market sell-off. The community is sharply divided, with many anticipating further declines and a retest of crucial support levels, while others expect an eventual 'buy the dip' recovery, viewing current fears as an overreaction.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive Phase 1 clinical trial results for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile even in treatment-resistant patients. This promising early data has ignited bullish sentiment about its blockbuster potential and possible short squeeze, despite community concerns surrounding a recently announced public offering to fund future trials.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to reports of exceptionally high-grade silver drill results across its vast land, significantly boosting optimism for future production. The community is actively discussing continuous insider buying by Eric Sprott and surging precious metal prices as catalysts for substantial upside, while also considering the company's non-producing status and potential for dilution. This confluence of factors, coupled with discussions of a possible short squeeze and growing silver demand, is driving intense conversation around the mining company.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and intense discussion, largely influenced by President Trump's remarks at the Davos World Economic Forum and ongoing geopolitical tensions. The community remains deeply divided, with many bears highlighting significant drops and questioning Bitcoin's safe-haven status amidst rising gold prices, while bulls emphasize strong accumulation by institutional players and technical indicators pointing to a potential rebound from leveraged short attacks.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel...

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire TEL AVIV, Israel, Nov. 18, 2025 Management to Hold...

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types BioLineRx Announces Receipt of USPTO Notice of Allowance for Key...

Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-new-pilot-phase-data-phase-2-combination">announced</a> positive data from the single-arm pilot phase of its Phase 2 trial evaluating its drug in the treatment of pancreatic cancer.The study is evaluating the company’s Motixafortide, Cemiplimab, and standard-of-care chemotherapies Gemcitabine and Nab-paclitaxel, versus Gemcitabine and Nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. Progression-free means that the patient's disease did not get worse or spread.CEO Philip Serlin said that the data emerging from the pilot phase of the study are “extremely encouraging,” while also noting that pancreatic cancer is the “most challenging” tumor to treat.The company also stated that it now plans to enroll 108 patients in the Phase 2 trial, which will be a randomized study, based on the results of the pilot phase. The company had previously planned to enroll only 30 patients in the study.The trial is planned to be fully enrolled in 2027. While the trial's primary endpoint is progression-free survival (PFS), secondary objectives include safety, response rate, disease control rate, duration of clinical benefit, and overall survival.Following the news, Jones Research upgraded BioLineRx to ‘Buy’ from ‘Hold’ with a $12 price target. With these results, BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial, assuming favorable Phase II results, the analyst said.On Stocktwits, retail sentiment around BLRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_12_47_05_PM_png_ca2195fcbe.webp" alt="BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits" width="626" height="68"><figcaption>BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> is down by about 50% this year and by about 84% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-eyeing-hiv-drug-rollout-in-low-income-countries-report/ch0ubVvRbuE">Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.

Equity

Nasdaq-listed shares of BioLineRx (BLRX) traded 4% higher on Tuesday afternoon after the company reported an over 600% year-on-year jump in its first-quarter net income.The Israel-based biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2025-financial-results-and-provides-corporate-update-302465635.html">reported</a> revenues for the three months ended March 31, 2025, of $0.3 million, compared to revenues of $6.9 million in the year-ago period, and below an analyst estimate of $1 million, as per Koyfin data.BioLineRx out-licensed its FDA-approved Aphexda, used in treating a type of cancer called multiple myeloma, to Ayrmid last November and shut its U.S. commercial operations by the year-end.Aphexda, however, generated sales of $1.4 million in the first quarter, providing the company with $0.3 million in royalties.The fall in revenue in the first quarter reflects the company’s change in operation after out-licensing Aphexda, it said.Net income for the quarter ended March 31, 2025, was $5.1 million, compared to $0.7 million for the quarter ended March 31, 2024, and above an estimated net loss of $3 million. The net non-operating income stood at $7.6 million, compared to net non-operating income of $4.5 million in the three months ended March 31, 2024.The company ended the quarter with cash, cash equivalents, and short-term bank deposits of $26.4 million, which it expects to be sufficient through the second half of 2026.CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda."I remain optimistic that we will announce a meaningful transaction this year," he said.On Stocktwits, retail sentiment around BioLineRx rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_1_49_08_PM_png_c44b3d7c0e.webp" alt="BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits " width="627" height="65"><figcaption>BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits&nbsp;</figcaption></figure><a href="https://stocktwits.com/symbol/BLRX">BLRX stock</a> is down by about 63% this year and nearly 87% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/byd-sued-by-brazil-prosecutors-for-alleged-human-trafficking/ch0V1GJRbra">BYD Sued By Brazil Prosecutors For Alleged Human Trafficking: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident

CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda. 

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Bioline Rx Ltd - ADR

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.38	--	--	N/A
Q3 '25	-$0.67	$0.00	100.00%	BEAT
Q2 '25	-$0.35	$0.00	100.00%	BEAT
Q1 '25	-$0.95	$0.00	100.00%	BEAT
Q4 '24	-$0.81	-$0.01	98.76%	BEAT

BLRX
BioLineRx, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BLRX News

BLRXBioLineRx, Ltd.